Key result
Statin therapy (OR 0.21; 95% CI 0.05-0.86) and clopidogrel therapy (OR 0.17; 95% CI 0.04-0.78) were associated with a significant reduction in death, MI, and stroke at 6 months in PAD patients.
Why the study?
Do statin and anti-platelet therapies reduce cardiovascular events in patients with peripheral arterial disease?
Observational
Do statin and anti-platelet therapies reduce cardiovascular events in patients with peripheral arterial disease?
Odds Ratio: 0.21 (95% CI 0.05–0.86)
p-value: p=0.03
Statin and clopidogrel therapies are associated with significantly reduced cardiovascular morbidity and mortality in patients with peripheral arterial disease.
Supports statin and clopidogrel use in PAD; leaves open need for randomized confirmation of benefit.
Peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis and is associated with a several-fold increased risk of cardiovascular morbidity and mortality. Statins and anti-platelet therapy have been unequivocally shown to be beneficial in patients with coronary artery disease, but minimal data exist on the effectiveness of these agents in patients with PAD and those undergoing peripheral vascular interventions. One recent study has demonstrated that statins are very effective as secondary preventive measures in patients with PAD but continue to be underutilized in this cohort. In our institutional peripheral interventional database, after adjustment for demographics and comorbidities, statin therapy (OR=0.21, 95% CI 0.05-0.86, p=0.03) and clopidogrel therapy (OR=0.17, 95% CI 0.04-0.78, p=0.02) were both associated with a significant reduction of the composite event rate of death, myocardial infarction and stroke at 6 months. In this article, we critically review the existing literature on the role of anti-platelet and statin therapy in reducing cardiovascular events in patients with PAD. Appropriate use of these agents may significantly decrease the cardiovascular morbidity and mortality of patients with PAD.
No takes yet. Share an insight, caveat, or question.
Dey et al. (2003) conducted an observational in Peripheral arterial disease (PAD). Statin and clopidogrel therapy vs. No statin or clopidogrel therapy was evaluated on Composite event rate of death, myocardial infarction and stroke (OR 0.21, 95% CI 0.05-0.86, p=0.03). Statin therapy (OR 0.21; 95% CI 0.05-0.86) and clopidogrel therapy (OR 0.17; 95% CI 0.04-0.78) were associated with a significant reduction in death, MI, and stroke at 6 months in PAD patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: